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Background: The gut microbiome is altered in Crohn’s disease. Although individual taxa have been correlated with
post-operative clinical course, global trends in microbial diversity have not been described in this context.
Methods: We collected mucosal biopsies from the terminal ileum and ascending colon during surgery and
post-operative colonoscopy in 6 Crohn’s patients undergoing ileocolic resection (and 40 additional Crohn’s and
healthy control patients undergoing either surgery or colonoscopy). Using next-generation sequencing technology,
we profiled the gut microbiota in order to identify changes associated with remission or recurrence of
inflammation.
Results: We performed 16S ribosomal profiling using 101 base-pair single-end sequencing on the Illumina GAIIx
platform with deep coverage, at an average depth of 1.3 million high quality reads per sample. At the time of
surgery, Crohn’s patients who would remain in remission were more similar to controls and more species-rich than
Crohn’s patients with subsequent recurrence. Patients remaining in remission also exhibited greater stability of the
microbiota through time.
Conclusions: These observations permitted an association of gut microbial profiles with probability of recurrence in
this limited single-center study. These results suggest that profiling the gut microbiota may be useful in guiding
treatment of Crohn’s patients undergoing surgery.
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Crohn’s disease is an inflammatory bowel disease (IBD)
with courses of recurrent inflammation, the etiology of
which is likely rooted in the interplay of gut microbial im-
balances (dysbiosis) and host immunity [1]. Culture-
independent studies of the gut microbiota in Crohn’s
disease have documented that at least a subset of patients
harbor microbial communities distinct from those in indi-
viduals without IBD [2-8]. The unpredictability of Crohn’s
disease renders sampling of patients prior to the onset of
inflammation inherently challenging. Here we addressed
this by studying patients undergoing surgery and following
them through the initial post-operative colonoscopies.* Correspondence: dey@post.harvard.edu
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reproduction in any medium, provided the orPatients were thereby effectively “synchronized” in the his-
tory of their disease by starting at a common event. This
design also permitted us to study the onset of inflamma-
tion after a state of known health (i.e., following the resec-
tion of all diseased bowel). Individual taxa, such as
Faecalibacterium prausnitzii, have been associated with
post-operative clinical course [9]. This finding raises the
question that we examined here: can profiling the gut
microbiota at large be a useful clinical tool?
We characterized the gut microbiota in 6 patients with
Crohn’s disease undergoing surgical resection of the ter-
minal ileum to remove all evident inflammation, a proce-
dure known as ileocolic resection. We collected samples
during surgery and the first post-operative colonoscopy.
We also characterized 5 Crohn’s patients undergoing sur-
gery alone, 9 patients without IBD undergoing ileocolic re-
section (due to a colonic polyp or cancer), and 26 patients
receiving only colonoscopy (15 with Crohn’s for the pur-
pose of assessing disease activity as per the discretion of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Dey et al. BMC Gastroenterology 2013, 13:131 Page 2 of 11
http://www.biomedcentral.com/1471-230X/13/131the treating gastroenterologist, 11 without IBD receiving
colorectal cancer screening) (Additional file 1: Table S1).
All patients were recruited via continuous enrollment from
a single medical center in the San Francisco Bay Area.
Crohn’s patients undergoing ileocolic resection are at
risk for post-operative recurrence of inflammation in the
newly terminal ileum: 65% have visible inflammation at
colonoscopy after 1 year [10]. Powerful anti-inflammatory
treatments can prevent or reduce this but are typically re-
served for patients at high risk for recurrence [10,11]. Gas-
troenterologists use clinical history and colonoscopy
(initially performed approximately six months after sur-
gery) to inform treatment decisions. At colonoscopy, mu-
cosal health is graded with the Rutgeerts score (0–1
indicates remission; 2–4, recurrence) [12], which informs
prognosis. The aim of the present study is to determine
whether profiling the gut microbiota can further inform
prognosis in this setting. We asked whether post-operative
recurrence could be correlated with microbiota of the
resected surgical tissue, either alone or in conjunction
with specimens obtained subsequently. Mucosal biopsies
were taken from the terminal ileum and ascending colon,
distinguishing between inflamed and healthy-appearing
mucosa. All biopsies from an individual patient at a given
time point were obtained with the same surgical or endo-
scopic instruments, consistent with previously published
protocols [3,5,13-15] but leading to the possibility of
cross-contamination. Fecal samples were obtained one day
prior to procedures when feasible. We performed micro-
bial profiling of samples based on deep sequencing of a
16S ribosomal gene region. Based on observed associa-
tions between species abundance and post-operative re-
currence, we propose that microbial profiling of patients
with Crohn’s disease undergoing surgery may serve as a
prognostic indicator for subsequent clinical course.
Methods
Human subjects
Patients scheduled for surgery and/or colonoscopy were
recruited to the study from the University of California,
San Francisco (UCSF), between November 2008 and
August 2010. No patients underwent a procedure speci-
fically for this study. Informed consent was obtained of
each patient by one of the authors (ND). The use of hu-
man subjects was approved by the Committee on Hu-
man Research (CHR) at UCSF (study 10–01519). All
samples analyzed were acquired specifically for this
study; none were taken from a tissue bank.
DNA extraction
Stool samples (250 mg) were homogenized in PowerBead
tubes (MoBio, Carlsbad, CA) using a Mini-BeadBeater-8
(BioSpec) at the highest setting for 1 minute. DNA was
extracted using the MoBio Power Soil DNA Kit (Carlsbad,CA) according to the manufacturer’s instructions.
Frozen biopsies (30 mg) were suspended in 600 μl of
Buffer RLT (Qiagen, Valencia, CA) that contained β-
Mercaptoethanol (1 μl per 100 μl of buffer), and trans-
ferred to silica-bead-containing tubes (Lysing Matrix
B, MP Biomedicals, Solon, OH). Tubes were placed
in a Mini-BeadBeater-8 (BioSpec) and homogenized
at the highest setting for 3 minutes. Samples were fur-
ther thawed in a 37°C water bath for 5 minutes. DNA
was subsequently extracted using the column-based
Qiagen AllPrep kit (Valencia, CA) as per manufacturer
instructions.
16S rRNA amplification
A fragment of the 16S ribosomal genes (containing the
V1-V3 hypervariable regions) was amplified by PCR with
9F-containing (5′-CAAGCAGAAGACGGCATACGAGA
TNNNNNNGTGACTGGAGCGAGTTTGATC [AC]TGG
CTCAG-3′) and 529R-containing (5′-AATGATCGGCGA
CCACCGAGATCTACACTCTTTCACCGCGGC[GT]GC
TGGC-3′) primers at a final concentration of 400 nM
using Phusion high-fidelity PCR Master Mix (Finnzymes).
(Adapter sequences are underlined. Sample-specific 6-mer
barcodes are represented by N’s. 9F and 529R sequences
are italicized.) 10 barcodes were used, in varying combina-
tions: AAGCTA, ACATCG, ATTGGC, CACTGT, CG
TGAT, CTGATC, GATCTG, GCCTAA, TCAAGT, and
TGGTCA. PCR conditions were as follows: 98°C initial
denaturation for 30 seconds; 10 cycles of 98°C for 10 sec-
onds, 53°C for 30 seconds, and 72°C for 30 seconds; a final
extension at 72°C for 5 minutes. Following PCR, the sam-
ple was run on a 1.5% agarose gel (Invitrogen UltraPure
agarose, Carlsbad, CA) at 80 Volts for 15 minutes. The
amplified fragment was then excised and purified using
GeneCatcher tips (the Gel Company, San Francisco, CA).
Technical triplicates were performed for each sample.
Illumina sequencing
Equimolar amounts of amplicons from 6–7 samples
were pooled for multiplexing on each flow cell lane.
The V3 hypervariable region was sequenced on an
Illumina Genome Analyzer IIx using standard reagents.
A custom sequencing primer (5′-GATCTACACTCTTT
CACCGCGGC[GT]GCTGGC-3′), which contained 529R
(italicized), was used to initiate sequencing beyond the
529R primer region, effectively increasing sequencing read
length of the region of interest. Despite this strategy, con-
servation in 16S sequence beyond the 529R primer region
required low cluster density on flow cells for successful se-
quencing. Matrix and phasing values generated from a li-
brary control lane were applied to the lanes containing the
amplified 16S fragments. We generated 23.3 gigabases of
101 base pair single-end reads of partial 16S ribosomal se-
quence data.
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Ribosomal sequence data was processed using tools from
the QIIME pipeline v1.2.1 [16]. Sequences were de-
replicated at 100% sequence identity. No chimeric se-
quences were seen using ChimeraSlayer [17]. Reads were
retained if they were present in at least two samples and
represented in at least ten times in the combined dataset.
No read trimming or filtering was performed based on Q
scores. Reads of presumed human DNA were identified
and removed if they both bore 100% sequence identity to
human DNA (reference human genome downloaded from
http://www.ncbi.nlm.nih.gov/genome/ on May 19, 2011)
and were not seen in the Greengenes ribosomal database
(downloaded from http://greengenes.lbl.gov/Download/
Sequence_Data/Greengenes_format/ on March 17, 2011).
Contaminant human DNA constituted 15% of sequences.
No contaminant fungal DNA was seen (18S fungal genes
downloaded from NCBI on May 19, 2011). 18.4 gigabases
of ribosomal sequence data were considered to be high
quality and included in our analysis. This total represented
a mean coverage of 1.3 million reads per sample ± 0.86
million [s.d.], with a range of 6,400-5,300,000 reads per
sample. 14 of the total 139 samples had fewer than
250,000 reads (9 Crohn’s, 5 non-IBD). The mean number
of reads per sample was not significantly different in
Crohn’s compared to non-IBD controls. The range for
samples from the six highlighted Crohn’s patients was
22,000-4,100,000 reads per sample. Reads were aligned
using PyNAST [18]. Phylogenetic trees were constructed
using FastTree [19]. The unique sequences were assigned
to known taxa, to the extent possible, using the RDP clas-
sifier [20]. The relative proportions of sequences repre-
sented by each taxa were averaged by patient per time
point prior to group comparisons, which were made with
the Student’s t-test (Welch two sample t-test) using values
from a single time point per patient as indicated in the
text.
Diversity calculations
Alpha diversity was measured using the Chao1 and Faith
phylogenetic diversity (PD) metrics [21,22]. Beta diversity
was measured using the weighted UniFrac metric [23].
UniFrac distance matrices generated via QIIME were used
to compute average distances within and between various
groups of samples (e.g. Crohn’s versus control biopsies).
The arithmetic mean of coordinates in each dimension
of the ordination space (i.e., the PCoA space, a multi-
dimensional Euclidean space) was taken to determine the
centroid. Autocorrelation, or pseudo-replication, was ac-
counted for by taking the centroid in ordination space of
all biopsies collected from a given individual at a given
time. For example, in comparing Crohn’s patients to con-
trol patients, the centroids of biopsies collected at patients’
initial procedures within this study were used todetermine average UniFrac distances. For comparisons
that involved multiple pairwise UniFrac distances for an
individual, such as inflamed versus healthy-appearing bi-
opsies within a Crohn’s patient, the average was used for
the overall calculation. Principal coordinates analysis
(PCoA) plots were generated in R [24] using the ggplot2
package [25]. The Student’s t-test with 1,000 Monte Carlo
simulations was used to identify statistically significant dif-
ferences between groups [26,27].
Heat map generation showing likelihood of recurrence or
remission
The two-sided Student’s t-test was used to compare sets
of weighted UniFrac distances between surgical biopsies
from Crohn’s patients and the following: surgical control
biopsies, biopsies from the same patient at the time of
the first post-operative colonoscopy, or all control biop-
sies (i.e., surgery and colonoscopy) (Additional file 2:
Figure S4A). In addition, for each Crohn’s patient under-
going surgery, intra-individual comparisons of surgical
biopsies were made (Additional file 2: Figure S4B). Like-
lihood heat maps were generated by overlaying distribu-
tions of weighted UniFrac distances in remission and
recurrence, then calculating the proportion of UniFrac
distances (in bins of width 0.1) seen in remission or re-
currence. Leave-one-out cross-validation analyses were
performed by generating a predictive model using the
aggregate of UniFrac distances from all but one patient,
and then “predicting” the clinical outcome of the ex-
cluded patient. We generated these predictions by com-
puting the average probability of recurrence arising from
each UniFrac distance. Statistical calculations were per-
formed in R [24]. Heat maps were generated using the
“heatmap.2” function in the gplots package [28].
Results
Deep sequencing of a 16S ribosomal RNA gene region
We amplified 16S ribosomal genes with 9F and 529R
primers. We used a 529R-containing custom sequencing
primer to initiate sequencing beyond the conserved pri-
mer sequence region and generate 101 base-pair single-
end reads of the V3 hypervariable region using the
Illumina GAIIx platform. A total of 139 samples were se-
quenced from 46 subjects. After filtering, our dataset was
comprised of 18.4 gigabases of high-quality reads (mean =
1.3 million reads per sample ± 0.86 million [s.d.]; range
6,400-5,300,000 reads) (see Methods for additional details).
The combined dataset contained 300,389 unique se-
quences, or 57,603 operational taxonomic units (OTUs)
when clustering by 97% nucleotide sequence identity. This
is a higher number of OTUs than previously reported to
be associated with human gut [26,29-32], but we sus-
pected this to be a consequence of sequencing error com-
bined with the deep level of coverage [33]. The region of
Dey et al. BMC Gastroenterology 2013, 13:131 Page 4 of 11
http://www.biomedcentral.com/1471-230X/13/13116S selected evolves at a rate similar to the 16S gene over-
all [34], so this is not likely to be a major source of differ-
ence. We confirmed this by simulating deep sequencing of
the gut microbiota. Using previously published datasets of
9,920 [26] and 7,208 [29] near-full-length 16S sequences,
we generated large datasets in silico of 200 million reads
(comparable to our combined dataset of 180 million
reads), adding mismatches at rates of 0.01%, 0.1%, or 0.5%
per base. Where the original samples contained 451 and
204 OTUs, respectively, the simulated deeply sequenced
samples with a 0.1% error rate contained 32,868 and
26,622 OTUs, confirming the prior observation that se-
quencing noise on the Illumina platform can inflate OTU
estimates [35]. With an error rate of 0.5% per base, we ob-
served 554,073 and 431,544 OTUs, respectively,
suggesting that – even if the 57,603 OTUs we observed do
not represent novel taxa revealed by deep sequencing but
instead can largely be accounted for by sequencing error –
the true sequencing error rate in our dataset was closer to
0.1% per base. We also performed the inverse experiment,
subsampling sets of 10,000 sequences from each of the gut
samples we collected, in order to estimate OTU counts
that might have been seen with shallower sequencing.
These subsamples contained 57–245 (95% confidence
interval) OTUs, similar to OTU counts at this sequencing
depth seen in prior studies [26,29].
Inter-individual heterogeneity in Crohn’s disease
We assessed similarity among samples using weighted
UniFrac, a beta diversity metric that accounts for both
the relative abundances of taxa in each sample and the
evolutionary distances among them [23]. In a principal
coordinates analysis (PCoA) plot based on pairwise
weighted UniFrac distances between samples (Figure 1A),
non-IBD patients appeared to cluster together. On the
other hand, Crohn’s patients were dispersed through-
out the PCoA plot. The gut microbiota in Crohn’s dis-
ease does not have a single composition; samples were
highly variable, and some were indistinguishable from
non-IBD controls. Comparing the centroids in ordin-
ation space (i.e., multi-dimensional PCoA space) of all
biopsies from each patient’s initial procedure within
this study, we found that the average weighted UniFrac
distance among Crohn’s patients (“Crohn’s vs Crohn’s”
in Figure 1B) was significantly greater than the average
distance among control patients (“control vs control”)
(P<0.005). In fact, the average distance among Crohn’s
patients (“Crohn’s vs Crohn’s”) was even greater than
the average distance between Crohn’s and control sam-
ples (“Crohn’s vs control”) (P<0.05), indicating that
Crohn’s patients are more different from each other
than they are from healthy patients. In particular,
Crohn’s patients undergoing surgery seemed to have
the greatest variability (Additional file 2: Figure S1).These observations are reflected in Figures 1C and D,
which show phylum-level classifications in a single ileal
or colonic sample, respectively, from each patient.
Still, several significant differences existed. The two
most common phyla in both Crohn’s and control sam-
ples were Bacteroidetes and Firmicutes (Figures 1C-D).
All biopsies considered, Crohn’s patients had greater
relative abundance of Proteobacteria (P<10-4) and Fuso-
bacteria (P<0.05), and lower relative abundance of
Bacteroidetes (P<10-4), compared to non-IBD patients
(Additional file 1: Table S3). Similar to several previous
reports [9,36,37], our data showed greater relative abun-
dance of Faecalibacterium in healthy patients compared
to Crohn’s patients, and Crohn’s remission patients com-
pared to Crohn’s recurrence patients; however, these dif-
ferences were non-significant. The role of F. prausnitzii
in the pathogenesis of Crohn’s disease is yet unclear
[38]. Consistent with previous observations, the family
Enterobacteriaceae was more abundant in Crohn’s pa-
tients in our study (P<10-3) [4,7,15]. The genus Ru-
minococcus was less abundant in surgical biopsies from
Crohn’s patients relative to non-IBD surgical controls
(P<0.05), in line with a study reporting lower levels of
Ruminococcus gnavus in Crohn’s disease [39]. In the
context of mixed reports [9,36,40-42], our data showed
lower abundance of Bacteroides in Crohn’s disease pa-
tients (P<10-2). The presence of discrepancies between
studies may represent species- or strain-level differences,
or be a consequence of the inter-individual heterogeneity
observed here and elsewhere [2,15,43].
Dysbiosis was neither localized nor specific to inflamed
mucosa. The average UniFrac distance between inflamed
biopsies and adjacent healthy-appearing biopsies from the
same individual taken at the same time (“inflamed vs
healthy-appearing biopsies” in Additional file 2: Figure S1)
was significantly less than the distance between inflamed
biopsies from different individuals (“inflamed vs inflamed
[between persons]”) (P<0.005), indicating that measured
microbial community composition is fairly consistent
around the ileocolic junction within a patient, regardless
of local inflammation. As noted above, this may be due in
part to cross-contamination. This held true for both com-
parisons within the same region (ileum or colon) or be-
tween regions (ileum versus colon) (Additional file 2:
Figure S1). Prior studies have reported mixed results to
this end [5,15,44,45]. These data also suggest that inflamed
biopsies in different patients vary in microbial compos-
ition, as supported by the comparison of the average dis-
tance between inflamed biopsies from different individuals
(“inflamed vs inflamed [between persons]” in Figure 1B)
with the average distance between inflamed biopsies from
an individual taken at a given time point (“inflamed vs in-
flamed [within individual]”) (P<0.05). Indeed, inflamed bi-





















































































































































Figure 1 Inter-individual variability of the gut microbiota is greater in Crohn’s disease than healthy controls. (A) Principal coordinates
analysis (PCoA) plot based on weighted UniFrac distances between biopsies from Crohn’s and non-IBD patients. Biopsies in Crohn’s patients were
taken of inflamed and healthy-appearing mucosa. Biopsies did not cluster by inflammation or location. (B) Average pairwise weighted UniFrac
distances (±s.e.m.) among subsets of biopsies. Asterisks indicate significant differences: * P<0.05; ** P<0.005 (Student’s t-test with 1,000 Monte
Carlo simulations). Phylum-level classifications of a single (C) ileal or (D) colonic sample from each patient’s initial procedure within this study.
The Rutgeerts score at post-operative colonoscopy is denoted below surgical samples from Crohn’s patients. Phyla are sorted from top to bottom
in overall decreasing prevalence.
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multiple varieties of dysbiosis. Finally, stool and biopsies
acquired concomitantly from a single individual were no
more similar to each other than biopsies (or stool) from
different individuals (Additional file 2: Figures S1, S2).
Surgical biopsies from Crohn’s patients who remain in
remission are more similar to controls
Of the 11 Crohn’s patients who underwent surgery, 6
had follow-up at our center during the study period and
provided usable samples (Additional file 1: Table S2;
Additional file 2: Figure S3 describes the other patients).
All six patients were on biological therapies at the time of
surgery: 5 were on adalimumab (anti-TNF-α) prior tosurgery; 1 had previously been on adalimumab but had re-
cently switched to natalizumab (anti-α4-integrin). Half of
these patients experienced recurrence at post-operative
colonoscopy. Surgical biopsies from patients with recur-
rence appeared to be outliers on the PCoA plot relative to
the main cluster of samples constituted largely by non-
IBD samples (Figure 2A). The average UniFrac distance
between surgical samples from Crohn’s patients and from
non-IBD controls was significantly greater in recurrence
than in remission (P=0.03; Figures 2B, Additional file 2:
Figure S4A). Patients who subsequently enjoyed remis-
sion at 6 months were more similar to the controls.
Large UniFrac distances to controls were rarely seen in
remission, while small distances were rare in recurrence
AD E
B C
Figure 2 Crohn’s patients with recurrence have significant dysbiosis at the time of surgery relative to control patients. (A) PCoA plot of
weighted UniFrac distances between all surgical biopsies and non-IBD colonoscopic biopsies, with Crohn’s surgical samples (red) sized according
to Rutgeerts score at post-operative colonoscopy. A Rutgeerts score of 2 or more indicates recurrence; less than 2, remission. (B) Average
weighted UniFrac distances (±s.e.m.) between Crohn’s surgical samples and surgical controls were significantly greater in recurrence. The asterisk
indicates a significant difference: * P<0.05. (C) Heat map showing probability of remission or recurrence based on weighted UniFrac distance to a
single surgical control biopsy, binned in increments of 0.1. Each row adds up to 1. Based on a single biopsy per Crohn’s patient, differences in
UniFrac distance distributions between remission and recurrence were not consistently significant, as demonstrated by (D) random selection of a
single surgical biopsy from each of the six Crohn’s patients and determination of UniFrac distance to a randomly selected control biopsy
(repeated 10,000 times), and (E) examination of all 486 combinations of pairwise comparisons between each surgical biopsy from the six Crohn’s
patients and the centroid in ordination space of control biopsies. Dark gray shaded bars indicate a P-value of less than 0.05.
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tribution of UniFrac distances to controls in remission
and recurrence.
Given these patterns, we asked whether a single surgi-
cal biopsy from a Crohn’s patient could be used to esti-
mate probability of recurrence or remission. We took
two approaches to studying this. First, we randomly se-
lected a single surgical biopsy from each of the six
Crohn’s patients and determined the UniFrac distance to
a randomly selected control biopsy. We then compared
the distributions of three distances from remission pa-
tients versus three distances from recurrence patients. A
different control biopsy was used for each comparison,
in order to test whether any observed differences were
robust to variation among controls. Repeating this exer-
cise 10,000 times, we found that these distributions weresignificantly different in 34% of cases, as defined by a P
value of less than 0.05 (Figure 2D). Second, we deter-
mined UniFrac distances from each Crohn’s surgical bi-
opsy to the centroid in ordination space of all control
biopsies. We compared distributions in remission versus
recurrence, examining all 486 combinations of pairwise
comparisons between each surgical sample from the six
Crohn’s patients and the centroid of control biopsies
(Figure 2E). The distributions of distances in remission
and recurrence were significantly different in 56% of
comparisons. Both of these calculations suggest that use
of a single biopsy specimen for prognostic purposes may
not be reliably useful.
We therefore examined the utility of combining infor-
mation from multiple biopsies. For each of the six
Crohn’s patients, we estimated outcome based on
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patients (Additional file 2: Figures S5, S6). In this
leave-one-patient-out cross-validation analysis, pairwise
UniFrac distances between surgical biopsies of the five-
patient “training set” and all controls were used to gen-
erate heat maps reflecting probabilities of recurrence
given a single UniFrac distance. We then computed the
probability of recurrence by averaging the probabilities
generated by each surgical biopsy from the “test patient.”
This scheme correctly predicted recurrence or remission
in all cases. In two cases, the correct prediction was
made with low confidence, based on a probability of 53-
55%; in the remaining cases, the signal was substantially
stronger, such that the mean probability associated with
all predictions in this leave-one-patient-out analysis was
79% ± 9%. Multiple biopsies appear to improve signal
despite the general trend that biopsies from a patient are
most similar to each other. This may relate to the incon-
sistency seen between biopsies from surgery in patients
with recurrence, discussed below.
Crohn’s patients with post-operative recurrence have less
consistency between surgical biopsies and less stability
through time
Crohn’s patients with recurrence exhibited less stable
microbiota through time. The average UniFrac distance
between the centroid of a patient’s surgical biopsies and
the centroid of the same patient’s post-operative biop-
sies was greater in recurrence than in remission (P<0.005;
Figure 3A). A similar but non-significant trend was seen
when we averaged the pairwise UniFrac distances among
surgical samples from an individual (i.e., the average of all
pairwise distances between inflamed ileum, healthy ileum,
and healthy colon from a single patient at the time of
surgery): Crohn’s patients with recurrence showed less
consistency (Additional file 2: Figure S4B). This may
underlie the above finding that multiple biopsies improve
prediction strength. These observations are reflected in the
taxonomic classifications of biopsies acquired from pa-
tients included in the longitudinal analysis: patients who
stay in remission appear to have a more even profile across
samples (Figures 1C-D, 3C). We used the distribution of
UniFrac distances through time (i.e., surgery compared
to post-operative colonoscopy for an individual) to gener-
ate heat maps showing probability of clinical outcomes
(Figure 3B, Additional file 2: Figure S4B). We validated our
model using a leave-one-patient-out approach as above.
Again, predictions were correct with varying levels of con-
fidence. In one case, confidence was low at 59%; in the
remainder, the signal was substantially stronger, such that
the mean probability associated with all predictions was
88% ± 8% (Additional file 2: Figure S7). Instability of
the gut microbiota through time may therefore be related
to recurrence. Interestingly, biopsies from post-operativecolonoscopies of all Crohn’s patients reflected a migration
toward the cluster of control biopsies, regardless of
Rutgeerts score (Additional file 2: Figure S8).
Reduced species richness in Crohn’s pronounced
in recurrence
Consistent with prior reports [2,4,15,46], we observed re-
duced alpha diversity (i.e., species richness) in the gut
microbiota of Crohn’s patients. In light of variations in se-
quencing depth, we subsampled sets of 10,000 sequences
from each sample, excluding the single sample with fewer
total reads (a colonic biopsy from a patient without IBD).
We observed 143 +/− 5 (s.e.m.) OTUs in patients with
Crohn’s disease, as compared to 176 +/− 6 (s.e.m.) OTUs
in non-IBD controls. The Chao1 nonparametric estimator
and the Faith phylogenetic diversity (PD) metric also indi-
cated reduced diversity in Crohn's patients compared to
controls (Additional file 2: Figures S9, S10) [21,22]. The
reduction in alpha diversity in Crohn’s was significant in
patients with recurrence with both Chao1 and PD metrics
relative to non-IBD controls (P<0.05). These data are con-
sistent with the hypothesis that a rich gut microbiota may
protect against disease.
We identified a limited number of significant taxonomic
differences in samples from Crohn’s patients with recur-
rence relative to those who stayed in remission. At surgery,
patients who would go on to experience recurrence had a
significantly lower relative abundance of the families
Lachnospiraceae (P<10-2) and Erysipelotrichaceae (P<0.05),
as well as an unidentified genus within Clostridia (P<10-2),
all members of the phylum Firmicutes (Additional file 1:
Table S3). Recurrence was associated with a greater abun-
dance of Rhodobacteraceae (of class Alphaproteobacteria;
P<0.05) and an unknown Proteobacteria (P<10-2). At post-
operative colonoscopy, the genus Rhizobium (also Alpha-
proteobacteria) was the lone significant difference between
Crohn’s patients experiencing recurrence and those re-
maining in remission, more abundant in patients with re-
currence (P<0.05).
Discussion
Understanding the gut microbiome in IBD is of interest
to both clinicians and patients, who are eager to predict
clinical course of the disease and identify appropriate
treatments to improve health outcomes, including pro-
biotics and diet [47]. Studying the etiologic role of the
gut microbiome in Crohn’s disease is challenging, due to
multiple issues including unpredictability of disease
course and patient selection. Many studies have charac-
terized patients at a single time point and attributed to
Crohn’s disease the observed microbial differences from
controls [2,4,7,15,36,37,42-46]. Global trends in diversity
have been underexplored. Here, we followed carefully
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Figure 3 Recurrence is associated with instability through time. (A) Average weighted UniFrac distances (±s.e.m.) between surgical and
post-operative colonoscopy biopsies for an individual. The asterisks indicate a significant difference: ** P<0.005. (B) Heat map showing probability
of remission or recurrence based on a single pairwise weighted UniFrac distance at surgery and post-operative colonoscopy, binned in
increments of 0.1. Each row adds up to 1. (C) Phylum-level classifications of biopsies acquired at surgery (“surg”) and post-operative colonoscopy
(“colo”) suggest greater stability in remission. Location (i = ileum; c = colon) and presence of inflammation at the biopsy site are indicated.
Dey et al. BMC Gastroenterology 2013, 13:131 Page 8 of 11
http://www.biomedcentral.com/1471-230X/13/131profiles with clinical course, synchronizing the time
course with ileocolic resection, and controlling for bio-
logic medication usage and geographic impact. Consist-
ent with prior reports suggesting translational utility of
gut microbial profiling in Crohn’s disease [9,48], we
show here that patients experiencing recurrence of in-
flammation after surgical resection of all diseased bowel
have distinct diversity profiles relative to patients who
remain in remission. A clinical test characterizing mul-
tiple biopsies from a surgically resected specimen may
ultimately be useful for informing prognosis.
While this study addresses several challenges of study de-
sign pertaining to variability and unpredictability in disease
course, it is also subject to certain limitations. The findings
presented here represent a small number of patients on
biologic therapies at a single medical center. Conceivably,
these findings may therefore only apply to a limited subset
of Crohn’s patients, whether it be patients on related medi-
cations or those in the study’s catchment population. Given
differences in study design, patient characteristics, sequen-
cing strategies, and other experimental variables, it is diffi-
cult to directly evaluate patients described in previous
studies in the context of our findings. The development of
a practical test based on these findings will require valid-
ation on a larger and more diverse patient population in-
volving multiple medical centers.
There were several questions we were unable to ad-
dress. We wished to collect fecal and biopsy samples at
all time points in order to examine the relationships of
both to outcomes. Unfortunately, we were only ablecollect fecal samples from already-enrolled Crohn’s pa-
tients concurrent with their post-operative colonoscopy.
Subsequent investigations examining the predictive cap-
acity of stool may build upon current knowledge of fecal
biomarkers [49], perhaps by focusing on patients with
inflammation of the distal gut or in patients who are not
otherwise scheduled for an invasive evaluation (e.g.
colonoscopy).
We also could not interpret the observed post-operative
“migration” of samples on the PCoA plot towards the
healthy controls in cases of both recurrence and remis-
sion. It is unclear whether this constituted some degree of
recovery from dysbiosis. Pre-operative data on the Crohn’s
patients or longitudinal data on the non-IBD surgical con-
trols may have enabled a better understanding of this mi-
gration. Future studies should evaluate pharmacologic or
dietary interventions in the context of microbial shifts
through time. Recent reviews of probiotics and prebiotics
in Crohn’s disease have underscored a lack of knowledge
in this area [50-53].
Conclusions
In summary, we demonstrated in this limited cohort at a
single medical center that analyses of surgical biopsies
using the UniFrac metric are associated with subsequent
clinical course. Whether the severity of dysbiosis or the
instability of the gut microbiota (or both) is the critical
determinant of recurrence in Crohn’s patients undergo-
ing surgery will need to be further explored. Whether
these influence inflammation or are the result thereof
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and does not appear to be specific to inflamed mucosa.
With apologies to Tolstoy, “unhappy guts” in Crohn’s
appear to be “unhappy” in different ways [54]. Taken
together with the broad spectrum of genetic mutations
associated with Crohn’s disease [55,56], it is not surpris-
ing that a specific cause has not been identified, and that
IBD patients require individualized care. Further studies
are warranted to validate these conclusions in a larger
set of patients and other clinical contexts.Additional files
Additional file 1: Table S1. Demographics and clinical characteristics of
study patients (numbers in parentheses), with a focus on the two sets of
patients discussed most extensively in the text: (A) Crohn’s patients with
recurrence or remission, and (B) Crohn’s patients and non-IBD control
patients. Table S2. Demographic and clinical data on patients studied
longitudinally. Table S3. P-values of differences in relative abundances of
taxa between (A) surgical biopsies from Crohn’s patients with recurrence
and those in remission (time point 1), (B) colonoscopic biopsies from
Crohn’s patients with recurrence and those in remission (time point 2),
(C) surgical biopsies from Crohn’s patients and controls, or (D) all biopsies
from Crohn’s patients and controls. Taxonomic strings are listed to the
deepest taxonomic rank that could be determined. Significant differences
(P < 0.05) are indicated in this table and color-coded to indicate which
group contains the higher proportion of the microbe: red for recurrence
(A,B) or Crohn’s (C,D); blue for remission (A,B) or controls (C,D); and gray
for non-significant. Taxa that did not have significant differences in any of
the four categories are not included in the table.
Additional file 2: Figure S1. Average weighted UniFrac distances (±s.e.m.)
among subsets of biopsies. Asterisks indicate significant differences: * P<0.05;
** P<0.005 (Student’s t-test with 1,000 Monte Carlo simulations). Figure S2.
PCoA plot of weighted UniFrac distances (A) between all samples acquired in
this study (stool is indicated with an asterisk) and (B) between stool samples
and biopsies acquired at the same time in 5 patients with Crohn’s disease, at
the first 1–2 postoperative colonoscopies. Figure S3. PCoA plot of weighted
UniFrac distances between all biopsies (i.e., from all patients at all time points)
denoting samples from Crohn’s patients who underwent surgery but were
excluded from predictive modeling. 1 patient was lost to follow-up. The
remaining 4 underwent post-op colonoscopy and were given Rutgeerts
scores of 0, 1, 2, and 3, referred to as patients 0–3, respectively, in this
discussion. Patient 0 was scheduled for ileocolic resection when recruited to
this study. However, an intra-operative decision was made to perform a
limited ileal resection combined with stricturoplasty. During postop
colonoscopy, the scope could not be advanced to the surgical anastomosis,
and so the Rutgeerts score (which was based on the visualized terminal
ileum) was not reflective of mucosal health at the anastomosis. Patient 1
agreed to provide surgical specimens but declined to provide biopsies at
post-op colonoscopy. Patient 2 had postop colonoscopy after the sample
collection period had ended. Patient 3 received postop colonoscopy at
another hospital but was described to have significant inflammation and
narrowing at the anastomosis, consistent with a score of 3. Figure S4.
Average weighted UniFrac distances (±s.e.m.) (A) between Crohn’s surgical
and all control biopsies, and (B) among surgical biopsies from an individual
Crohn’s patient, demonstrating differences in remission versus recurrence.
The asterisk indicates a significant difference: * P<0.05; ns, non-significant.
Figure S5. Leave-one-out validation testing of heat maps for generating
predictions regarding postoperative recurrence in Crohn’s patients using
weighted UniFrac distances between biopsies taken at surgery and surgical
controls. The post-operative Rutgeerts score is shown on the left (remission =
1–0; recurrence = 2 or more). The distribution of UniFrac distances for each
patient is represented as the top box plot in each set of three. The
subsequent two box plots in each set are the distributions of UniFrac
distances in the remaining 5 patients, distinguishing those who had
recurrence from those in remission. Heat maps on the right were generatedfrom these distributions to reflect probabilities of recurrence or remission
given a single UniFrac distance. Figure S6. Leave-one-out validation testing of
heat maps for generating predictions regarding postoperative recurrence in
Crohn’s patients using weighted UniFrac distances between biopsies taken at
surgery and all control biopsies (taken from surgery and colonoscopy).
The post-operative Rutgeerts score is shown on the left (remission = 0–1;
remission = 2 or more). The distribution of UniFrac distances for each patient
is represented as the top box plot in each set of three. The subsequent two
box plots in each set are the distributions of UniFrac distances in the
remaining 5 patients, distinguishing those who had recurrence from those in
remission. Heat maps on the right were generated from these distributions to
reflect probabilities of recurrence or remission given a single UniFrac distance.
Figure S7. Leave-one-out validation testing of heat maps for generating
predictions regarding postoperative recurrence in Crohn’s patients using
weighted UniFrac distances between biopsies taken at surgery and at post-
operative colonoscopy. The post-operative Rutgeerts score is shown on the
left (remission = 0–1; remission = 2 or more). The distribution of UniFrac
distances for each patient is represented as the top box plot in each set of
three. The subsequent two box plots in each set are the distributions of
UniFrac distances in the remaining 5 patients, distinguishing those who had
recurrence from those in remission. Heat maps on the right were generated
from these distributions to reflect probabilities of recurrence or remission
given a single UniFrac distance. Figure S8. PCoA plots of weighted UniFrac
distances between all samples acquired in this study, with each panel
highlighting the progression through time of an individual patient. The top
row shows patients who went into remission (Rutgeerts scores of 0 or 1); the
bottom row shows patients who had recurrence (Rutgeerts scores of 2).
Figure S9. Alpha diversity as measured using the chao1 metric, comparing
(A) control versus Crohn’s samples and (B) surgical biopsies of Crohn’s
patients who go on to have recurrence versus those who stay in remission,
compared to surgical control biopsies. The asterisk indicates a significant
difference: * P<0.05. Figure S10. Alpha diversity as measured using
phylogenetic diversity, comparing (A) control versus Crohn’s samples and
(B) surgical biopsies of Crohn’s patients who go on to have recurrence
versus those who stay in remission, compared to surgical control biopsies.
The asterisk indicates a significant difference: * P<0.05.
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